Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland - June 8, 2023 - ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for
The high-profile appointment reflects [Arriello s|https://arriello.com/] ambition to fully integrate its Regulatory/QA & Pharmacovigilance services in t.
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland - September 30, 2021 - ObsEva SA (NASDAQ: OBSV) (SIX: OBSN), a biopharmaceutical company developing